Path Healthcare Systems Corp. announced that it has received $120 million in funding from Andreessen Horowitz LLC, BoxGroup Services, LLC, Eli Lilly and Company, Granger Management LLC, Matrix Management Corporation, VXI Capital Management LLC

Eli Lilly (LLY) secured exclusive worldwide rights to products from its expanded Gate Bioscience partnership, with potential payments exceeding $870 million. Shares rose 1.6% to $1,161.50. The deal focuses on early-stage drug discovery, with revenue far in the future. Lilly will handle later development, trials, and commercialization.

Novo and Eli Lilly presented findings at a conference suggesting their GLP-1 weight-loss drugs may slow biological aging. Novo's semaglutide and Lilly's tirzepatide showed reductions in biological age of 2-4 years in overweight or diabetic patients. Both drugs are among the best-selling globally, with Lilly's tirzepatide generating $36B in 2023 revenue. The studies used proteomic and epigenetic clocks to measure aging effects.

Eli Lilly (LLY) announced the completion of a Phase 1 trial for Eltrekibart (LY3041658), an injectable drug. The study, which began in April 2026, focuses on safety, dosage behavior, and formulation. While Phase 1 data typically do not impact stock prices, they support long-term confidence in Lilly's pipeline. The trial's status was updated on October 5, 2026, with data cleaning and reporting ongoing.

Eli Lilly (LLY) presented data at a diabetes meeting showing its oral GLP-1 pill, Foundayo, achieved greater weight loss and better blood sugar control than oral semaglutide 25 mg in type 2 diabetes patients. The comparison was indirect, with a small advantage for Foundayo. LLY's forward P/E is 30.93x, below its historical average, reflecting slowing growth. EPS is forecasted to grow 52.62% in 2026 and 28.80% in 2027. Hedge fund ownership increased, and short interest is low.

Eli Lilly reported clinical trial data for a new combination therapy of Mounjaro (tirzepatide) and eloralintide, showing 2.9% reduction in hemoglobin A1c and 23% weight loss in type 2 diabetes patients. The drug targets multiple gut hormone pathways, offering significant metabolic changes. Common side effects include nausea and gastrointestinal issues, with rare risks like pancreatitis and gallbladder disease.

Eli Lilly (LLY) expanded its partnership with Gate Bioscience, committing up to $870m for exclusive global rights to develop molecular gate therapies. Lilly will support drug discovery and pay royalties on global sales. The deal focuses on a new target, with an option for a second. Lilly's commercial success, driven by tirzepatide (Mounjaro, Zepbound), funds its pipeline expansion.